Locally Advanced Hepatocellular Carcinoma Clinical Trial
Official title:
A Multinational, Double-blind, Placebo-Controlled, Parallel Randomized Arms, Phase II Trial to Compare Safety and Efficacy of Selective Internal Radiation Therapy (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab) Versus Selective Internal Radiation Therapy (SIRT-Y90) Followed by Placebo in Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
This is a multi-national, phase II, parallel-arm, double-blind, placebo-controlled, two-arm study designed to assess the efficacy and safety of SIRT-Y90 followed by atezolizumab plus bevacizumab [study arm], versus SIRT-Y90 followed by placebo [control arm] in patients with locally advanced Hepatocellular Carcinoma (HCC).
This study will enroll 176 patients randomized in a 1:1 allocation ratio (88 in each arm) to one of the two arms. - Study arm: SIRT-Y90 + 1200mg atezolizumab + 15mg/kg bevacizumab - Control arm: SIRT-Y90 + placebos (IV) The patients will be recruited from up to 13 sites from the Asia-Pacific Hepatocellular Carcinoma (AHCC) Trials Group (subjected to feasibility studies and ethics approval). Proposed sites are in Singapore, China, South Korea, and Taiwan. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05040438 -
Natural Killer (NK) Cell Therapy in Locally Advanced HCC
|
Phase 2 | |
| Recruiting |
NCT05168163 -
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
|
Phase 2 | |
| Completed |
NCT03299946 -
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
|
Phase 1 | |
| Recruiting |
NCT05269381 -
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05199285 -
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
|
Phase 2 | |
| Withdrawn |
NCT05327738 -
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04605731 -
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06066138 -
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
|
Phase 1 | |
| Not yet recruiting |
NCT05733598 -
RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC
|
Phase 2 |